Gene therapy and the adeno‐associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Voretigene neparvovec‐rzyl was recently approved for the treatment of Leber congenital amaurosis, and the use of gene therapy for eye disease is attracting even greater interest. The eye has immune privileged status, is easily accessible, requires a reduced dosage of therapy due to its size and is highly compartmentalized, significantly reducing systemic spread. Adeno‐associated virus (AAV), with its low pathogenicity, prolonged expression profile and ability to transduce multiple cell types, has become the leading gene therapy vector. Target diseases have moved beyond currently untreatable inherited dystrophies to common, partially treatable acquired conditions such as exudative age‐related macular degeneration and glaucoma, but use of the technology in these conditions imposes added obligations for caution in vector design. This review discusses the current status of AAV gene therapy trials in genetic and acquired ocular diseases, and explores new scientific developments, which could help ensure effective and safe use of the therapy in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“The reasons for the lack of longevity in these early trials are unclear but it was noted that the decline after initial improvement was associated with vectors that were driven using a cell-specific retinal pigment epithelium (RPE) promoter, while in other trials for LCA, a ubiquitous CBA promoter was used in the vect…”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Defective myosin VIIA gene responsible for Usher syndrome type IB
Well, D., Blanchard, S., Kaplan, J., Guilford, P., Gibson, F., Walsh, J., Mburu, P., Varela, A., Levilliers, J., Weston, M. D., et al. (1995) · Nature · doi:10.1038/374060a0 · Cited by 1,068
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“Unlike retroviruses and lentiviruses, rAAV also largely exists as extragenomic episomes and seldom integrates into the host genome, thus decreasing the risk of insertional mutagenesis.(10,11) Additionally, importantly in the neural tissues of the eye, the rAAV retains an ability to transduce both dividing and nondivid…”
BackgroundMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 2×
“In 2014, initial findings from a phase I/II multicentre clinical trial was published (NCT01461213).(59) Six patients with choroideremia, ranging from 35 to 63 y of age and representing different stages of the disease were treated with an AAV2 vector (AAV2.”
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 2×
“A similar decline after initial improvement was seen in an earlier LCA trial by Bainbridge et al, where 50% of the treated patients who showed an initial improvement within 6-12 mo had a decline in retinal sensitivity by their 3-y follow-up.(27) However, follow-up from patients who received voretigene neparvovec-rzyl…”
BackgroundResult
Research works printed but not linked: 121
- 10.1007/978-1-60761-938-3_5 · DOI · Paper page
- Daiger SP, 1998, Data services and software for identifying genes and mutations causing retinal degeneration, Invest. Ophthalmol. Vis. Sci., 39, S295
- 10.1016/j.preteyeres.2018.08.003 · DOI
- 10.1038/gt.2008.66 · DOI
- 10.1002/jcb.21819 · DOI
- Vincent KA, 1997, Analysis of recombinant adeno‐associated virus packaging and requirements for rep and cap gene products, J Virol, 71, 1897, 10.1128/jvi.71.3.1897-1905.1997 · DOI · Paper page
- 10.1136/bjo.2009.174912 · DOI · Paper page
- 10.1016/j.survophthal.2004.04.003 · DOI · Paper page
- Weleber RG, 1993, Leber Congenital Amaurosis
- 10.12998/wjcc.v3.i2.112 · DOI · Paper page
- 10.1093/hmg/ddu588 · DOI
- 10.1002/jgm.278 · DOI · Paper page
- 10.1073/pnas.1218933110 · DOI · Paper page
- 10.1038/sj.gt.3302861 · DOI · Paper page
- 10.1167/iovs.02-0595 · DOI · Paper page
- 10.1007/s10633-005-3159-0 · DOI
- 10.1016/j.ymthe.2005.08.008 · DOI · Paper page
- 10.1038/gt.2012.63 · DOI
- 10.1038/gt.2010.111 · DOI · Paper page
- 10.1089/hum.2013.146 · DOI · Paper page
- 10.1001/archophthalmol.2011.298 · DOI · Paper page
- 10.1016/j.ophtha.2016.03.003 · DOI · Paper page
- 10.1101/cshperspect.a017285 · DOI
- 10.1016/S0140-6736(17)31868-8 · DOI · Paper page
- 10.1056/NEJMoa1412965 · DOI · Paper page
- 2018, Voretigene neparvovec‐rzyl (Luxturna) for inherited retinal dystrophy, Med Lett Drugs Ther, 60, 53
- 10.1016/j.ophtha.2012.11.048 · DOI · Paper page
- 10.1097/APO.0000000000000227 · DOI
- 10.1093/hmg/9.4.645 · DOI · Paper page
- 10.1038/sj.gt.3302460 · DOI
- 10.1016/S1525-0016(03)00144-8 · DOI
- 10.1080/14712598.2018.1389886 · DOI
- 10.1167/iovs.12-11541 · DOI
- 10.1038/gt.2015.93 · DOI · Paper page
- MacDonald IM, 1993, Choroideremia
- 10.1371/journal.pone.0151943 · DOI
- 10.1016/j.ophtha.2009.01.016 · DOI
- Choroideremia KJ, 1986, A clinical and genetic study of 84 Finnish patients and 126 female carriers, Acta Ophthalmol Suppl, 176, 1
- 10.1016/S0161-6420(98)99031-5 · DOI
- 10.1586/14737159.4.4.478 · DOI
- 10.1016/j.ophtha.2016.10.022 · DOI
- 10.1073/pnas.051606598 · DOI · Paper page
- 10.1167/iovs.13-13454 · DOI · Paper page
- 10.1167/iovs.09-4892 · DOI
- 10.1016/S0161-6420(00)00643-6 · DOI
- 10.1002/jgm.2768 · DOI · Paper page
- 10.1126/scitranslmed.3002103 · DOI · Paper page
- 10.1136/bjophthalmol-2014-306505 · DOI · Paper page
- 10.1007/s12035-007-0025-y · DOI
- 10.1038/935 · DOI · Paper page
- 10.1093/hmg/9.14.2107 · DOI · Paper page
- 10.1086/341835 · DOI · Paper page
- 10.1073/pnas.0907720106 · DOI · Paper page
- 10.1016/j.ajhg.2012.07.006 · DOI · Paper page
- 10.1038/ng.3319 · DOI · Paper page
- 10.1038/sj.ejhg.5201269 · DOI · Paper page
- Fischer MD, 2016, Safe delivery of rAAV8.CNGA3 in patients with achromatopsia, Ophthalmologica, 236, 30
- 10.1038/nm1596 · DOI · Paper page
- 10.1136/bjo.79.7.697 · DOI · Paper page
- Rao P, 2018, Congenital X‐linked retinoschisis: an updated clinical review, Asia Pac J Ophthalmol (Phila)
- 10.1007/0-387-32442-9_39 · DOI
- 10.1038/gt.2009.61 · DOI
- 10.1086/346066 · DOI · Paper page
- 10.1038/sj.ejhg.5201828 · DOI · Paper page
- Yu‐Wai‐Man P, 1993, Leber Hereditary Optic Neuropathy
- 10.3109/08820538.2015.1115251 · DOI
- 10.1517/21678707.2015.1098531 · DOI
- 10.1001/archneur.62.5.730 · DOI · Paper page
- 10.1089/hum.2008.090 · DOI
- 10.1001/jamaophthalmol.2013.7971 · DOI · Paper page
- 10.1186/s40662-016-0063-5 · DOI · Paper page
- 10.1016/S2214-109X(13)70145-1 · DOI · Paper page
- 10.1155/2015/138070 · DOI · Paper page
- Weber BH, 2014, The role of the complement system in age‐related macular degeneration, Dtsch Arztebl Int, 111, 133
- 10.1016/j.molimm.2015.02.032 · DOI
- 10.1016/j.pop.2015.05.009 · DOI
- 10.1586/17512433.2015.990379 · DOI
- 10.1126/science.285.5425.245 · DOI · Paper page
- 10.1089/hum.2006.17.167 · DOI · Paper page
- 10.1016/S0002-9440(10)61697-5 · DOI
- 10.1002/jcp.1114 · DOI · Paper page
- 10.1126/science.286.5448.2244 · DOI · Paper page
- Mori K, 2002, AAV‐mediated gene transfer of pigment epithelium‐derived factor inhibits choroidal neovascularization, Invest Ophthalmol Vis Sci, 43, 1994
- 10.1007/978-1-4614-3209-8_86 · DOI
- 10.1371/journal.pone.0152589 · DOI
- 10.1089/hum.2006.088 · DOI · Paper page
- McClements ME, 2017, Adeno‐associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes, Yale J Biol Med, 90, 611
- 10.1038/gt.2013.3 · DOI · Paper page
- 10.1002/biot.201400529 · DOI
- Blacharski PA, 1988, Fundus flavimaculatus, 135
- 10.1371/journal.pone.0094272 · DOI · Paper page
- 10.1073/pnas.92.21.9815 · DOI · Paper page
- 10.1242/jcs.02636 · DOI · Paper page
- Udovichenko IP, 2002, Actin‐based motor properties of native myosin VIIa, J Cell Sci, 115, 445, 10.1242/jcs.115.2.445 · DOI · Paper page
- 10.1016/j.jmb.2009.03.047 · DOI
- 10.1038/jcbfm.2010.90 · DOI
- 10.1016/j.omtm.2017.04.008 · DOI
- 10.1073/pnas.95.7.3978 · DOI · Paper page
- 10.1073/pnas.91.5.1632 · DOI · Paper page
- 10.1038/sj.gt.3302791 · DOI · Paper page
- Pease ME, 2000, Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma, Invest Ophthalmol Vis Sci, 41, 764
- 10.1167/iovs.11-8484 · DOI
- 10.1073/pnas.1706193114 · DOI · Paper page
- 10.1038/gt.2011.142 · DOI
- 10.1038/eye.2000.126 · doi:10.1038/eye.2000.126
- 10.1186/s40662-015-0026-2 · DOI · Paper page
- Layton C, 2006, Aspects of Diabetic Retinal Neuropathy
- 10.1111/ceo.12795 · DOI
- 10.1016/j.pharmthera.2017.01.003 · DOI
- Danser AH, 1994, Angiotensin levels in the eye, Invest Ophthalmol Vis Sci, 35, 1008
- 10.1210/jcem-68-1-160 · DOI · Paper page
- 10.1038/jcbfm.2008.154 · doi:10.1038/jcbfm.2008.154
- 10.1038/mt.2011.155 · DOI · Paper page
- 10.1016/j.ajpath.2016.01.023 · DOI
- 10.1038/labinvest.2015.135 · DOI
- Ideno J, 2007, Prevention of diabetic retinopathy by intraocular soluble flt‐1 gene transfer in a spontaneously diabetic rat model, Int J Mol Med, 19, 75
- 10.1016/j.preteyeres.2018.01.004 · DOI
- 10.1371/journal.pone.0035318 · DOI
- 10.1038/srep22131 · DOI
- 10.1038/mt.2012.194 · DOI · Paper page
- 10.1038/nbt0315-217 · DOI
Cited by
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Self-citationThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“9|September 2021 optic neuropathy, retinitis pigmentosa, X-linked juvenile retinoschisis and more (Dalkara et al., 2016; Trapani and Auricchio, 2018; Ramlogan-Steel et al., 2019).”
BackgroundInfluential
Metadata
- Authors
- Ramlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B., Steel, J. C., & Layton, C. J.
- Venue
- Clinical & Experimental Ophthalmology
- Publisher
- Wiley
- Published
- 2019-01-02
- Volume
- 47
- Issue
- 4
- Pages
- 521-536
- ISSN
- 1442-6404 (ISSN-L)
- 1442-9071
- OpenAlex
- W2897417813
- Cited by
- 57
- References
- 32
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Gallipoli Medical Research Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy and the adeno‐associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations. https://app.cochat.ai/papers/10.1111/ceo.13416
- The paper
- Ramlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B., Steel, J. C., & Layton, C. J. (2019). Gene therapy and the adeno‐associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.13416
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.